NCT04141475

Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Centre Hospitalier Universitaire de Nice · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.

Conditions

• Diabetic Cardiomyopathies

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Physiomance acide lipoïque gold	1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
DIETARY_SUPPLEMENT	Placebo - Physiomance acide lipoïque gold	1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks

Timeline

• Start date: 2020-11-24
• Primary completion: 2023-11-01
• Completion: 2023-12-01
• First posted: 2019-10-28
• Last updated: 2024-02-05

Locations

1 site across 1 country: France